MabPlex Manufactured Monoclonal Antibody Receives IND Approval from the U.S. Food and Drug Administration
January 17, 2019

MabPlex International Announces Appointment of Dr. Wei Chen (Ph.D) as Chief Executive Officer

MabPlex International Ltd (MabPlex) has appointed Wei Chen Ph.D as the company’s new Chief Executive Officer (CEO). Dr. Chen, a senior biopharmaceutical professional who has participated in the development of many novel therapeutic agents, will be responsible for MabPlex’s strategic planning and operations management, including the company’s Chemistry, Manufacturing and Controls (CMC) operations.

Comments are closed.